Last reviewed · How we verify
Danhong injection
Danhong injection is a traditional Chinese medicine preparation that promotes blood circulation and removes blood stasis to improve microcirculation and reduce ischemic injury.
Danhong injection is a traditional Chinese medicine preparation that promotes blood circulation and removes blood stasis to improve microcirculation and reduce ischemic injury. Used for Acute myocardial infarction, Unstable angina pectoris, Ischemic stroke.
At a glance
| Generic name | Danhong injection |
|---|---|
| Also known as | A kind of injection made from two kind of Chinese herbs: Salvia miltiorrhiza and Safflower. |
| Sponsor | China Academy of Chinese Medical Sciences |
| Drug class | Traditional Chinese medicine injection |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
The injection contains active compounds from Salvia miltiorrhiza and Carthamus tinctorius that work synergistically to dilate blood vessels, inhibit platelet aggregation, and reduce blood viscosity. These effects improve tissue perfusion and oxygen delivery, particularly in ischemic conditions. The mechanism is consistent with traditional Chinese medicine theory of promoting qi and blood flow while removing stagnation.
Approved indications
- Acute myocardial infarction
- Unstable angina pectoris
- Ischemic stroke
Common side effects
- Injection site reactions
- Dizziness
- Nausea
- Allergic reactions
Key clinical trials
- Investigating the Clinical Benefits and Underlying Mechanisms of Danhong Injection in Modulating Mitochondrial Homeostasis Against Sepsis-Associated Myocardial Dysfunction (PHASE2)
- Danhong Injection in the Treatment of Acute Ischemic Stroke (PHASE4)
- Multi-"Omics" Research of Danhong Injection to Treat Acute Ischemic Stroke (PHASE4)
- Danhong Injection in the Treatment of Unstable Angina Pectoris (PHASE4)
- Danhong Injection in the Treatment of Chronic Stable Angina (PHASE4)
- the Effect of Danhong Injection on Microcirculation in the Treatment of Patients With STEMI After the PTCA Surgery. (PHASE4)
- A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Danhong injection CI brief — competitive landscape report
- Danhong injection updates RSS · CI watch RSS
- China Academy of Chinese Medical Sciences portfolio CI